Inflammatory mediator antagonists

Abstract

The present invention relates to pharmaceutical compositions comprising a unit dose of at least 1 mg of an antibody to oncostatin M (OSM) and a pharmaceutically acceptable carrier. In some aspects, the pharmaceutical composition comprises an antibody that blocks OSM from interacting with OSM receptor gp130.

1 . A pharmaceutical composition comprising a unit dose of at least 1 mg of an antibody to oncostatin M (OSM) and a pharmaceutically acceptable carrier.  
     
     
         2 . The pharmaceutical composition of  claim 1 , wherein the antibody further comprising an immunosuppresive, tolerance inducing, and anti-inflammatory agent.  
     
     
         3 . The pharmaceutical composition of  claim 1 , further comprising an agent selected from the group consisting of: an immunosuppresive, tolerance inducing, and anti-inflammatory agent.  
     
     
         4 . The pharmaceutical composition of  claim 1  further comprising a CD4+T cell inhibiting agent, an anti-CD23 antibody and a tumor necrosis factor (TNF) antagonist.  
     
     
         5 . The pharmaceutical composition of  claim 1  further comprising an agent selected from the group consisting of: a CD4+T cell inhibiting agent, an anti-CD23 antibody and a tumor necrosis factor (TNF) antagonist.  
     
     
         6 . The pharmaceutical composition of  claim 1 , wherein the antibody is an antibody to the mature form of SEQ ID NO:12.  
     
     
         7 . The pharmaceutical composition of  claim 1 , wherein said antibody reduces the TNFα secretion from macrophages in said patient.  
     
     
         8 . The pharmaceutical composition of  claim 1 , wherein said antibody interacts with one or more of the residues G120, Q16, Q20, N123, or N124 of human oncostatin M as set forth in the mature form of SEQ ID NO:12.  
     
     
         9 . The pharmaceutical composition of  claim 1  wherein antibody is an antagonist of OSM receptor gp130.  
     
     
         10 . The pharmaceutical composition of  claim 1 , wherein the antibody blocks OSM from interacting with OSM receptor gp130.  
     
     
         11 . The pharmaceutical composition of  claim 10 , wherein the antibody blocks OSM from interacting with OSM receptor gp130 type II.  
     
     
         12 . The pharmaceutical composition of  claim 10 , wherein said antibody blocking of OSM and gp130 receptor is concentration-dependent.  
     
     
         13 . The pharmaceutical composition of  claim 1 , wherein the antibody is a monoclonal antibody.  
     
     
         14 . The pharmaceutical composition of  claim 1 , wherein the antibody is humanized or chimerized.  
     
     
         15 . The pharmaceutical composition of  claim 1 , wherein said antibody prevents or reduces collagen release from cartilage.  
     
     
         16 . The pharmaceutical composition of  claim 1 , wherein said antibody prevents or reduces cartilage degradation.  
     
     
         17 . The pharmaceutical composition according to  claim 1  wherein said patient suffers from an inflammatory disorder selected from the group of: rheumatoid arthritis, psoriatic arthritis, juvenile arthritis, inflammatory osteoarthritis, reactive arthritis, Crohn's disease, ulcerative colitis, gastritis, asthma, chronic obstructive pulmonary disease, Alzheimer's disease, multiple sclerosis and psoriasis.